Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
Aclarion, Inc. (Nasdaq: ACON) has launched a program to develop a statewide network of providers in New Jersey utilizing Nociscan for personal injury and workers compensation cases. Led by Dr. Justin Kubeck of Ocean Pain and Spine, the initiative aims to improve objective evaluation of chronic low back pain patients in these complex legal scenarios. Nociscan's AI technology measures biomarkers in lumbar discs correlated to pain and structural integrity, providing objective data for treatment recommendations and legal defenses.
The average settlement for personal injury claims involving neck and back in New Jersey is $918,967, while work-related accidents causing such injuries have a national average settlement of $148,750. Aclarion plans to expand this model to other U.S. markets, targeting a population well-suited for advanced biomarker identification through the Nociscan platform.
Aclarion, Inc. (Nasdaq: ACON) ha lanciato un programma per sviluppare una rete regionale di fornitori nel New Jersey utilizzando Nociscan per casi di infortuni personali e indennità per i lavoratori. Guidata dal Dr. Justin Kubeck di Ocean Pain and Spine, l'iniziativa si propone di migliorare la valutazione obiettiva dei pazienti affetti da dolore cronico alla schiena in questi scenari legali complessi. La tecnologia AI di Nociscan misura biomarcatori nei dischi lombari correlati al dolore e all'integrità strutturale, fornendo dati oggettivi per raccomandazioni di trattamento e difese legali.
Il risarcimento medio per le richieste di risarcimento dovute a infortuni personali che riguardano collo e schiena nel New Jersey è di $918.967, mentre gli incidenti sul lavoro che causano tali infortuni hanno un risarcimento medio nazionale di $148.750. Aclarion prevede di espandere questo modello ad altri mercati americani, mirati a una popolazione ben adatta per l'identificazione avanzata dei biomarcatori attraverso la piattaforma Nociscan.
Aclarion, Inc. (Nasdaq: ACON) ha lanzado un programa para desarrollar una red estatal de proveedores en Nueva Jersey utilizando Nociscan para casos de lesiones personales y compensación laboral. Dirigido por el Dr. Justin Kubeck de Ocean Pain and Spine, la iniciativa tiene como objetivo mejorar la evaluación objetiva de los pacientes con dolor lumbar crónico en estos complejos escenarios legales. La tecnología AI de Nociscan mide biomarcadores en los discos lumbares correlacionados con el dolor y la integridad estructural, proporcionando datos objetivos para recomendaciones de tratamiento y defensas legales.
El asentamiento promedio por reclamos de lesiones personales que involucran el cuello y la espalda en Nueva Jersey es de $918,967, mientras que los accidentes laborales que causan tales lesiones tienen un asentamiento promedio nacional de $148,750. Aclarion planea expandir este modelo a otros mercados de EE. UU., dirigiéndose a una población bien adecuada para la identificación avanzada de biomarcadores a través de la plataforma Nociscan.
Aclarion, Inc. (Nasdaq: ACON)은 뉴저지에서 개인 상해 및 산업재해 사건에 대한 공급자 주 네트워크를 개발하기 위해 Nociscan을 활용하는 프로그램을 시작했습니다. Ocean Pain and Spine의 Dr. Justin Kubeck가 이끄는 이 이니셔티브는 이러한 복잡한 법적 시나리오에서 만성 요통 환자의 객관적인 평가를 개선하는 것을 목표로 하고 있습니다. Nociscan의 AI 기술은 통증 및 구조적 무결성과 연관된 요추의 바이오마커를 측정하여 치료 권고 및 법적 방어를 위한 객관적인 데이터를 제공합니다.
뉴저지에서 목과 허리 부상 관련 개인 상해 청구의 평균 합의금은 $918,967이며, 이러한 부상을 초래하는 작업 관련 사고의 전국 평균 합의금은 $148,750입니다. Aclarion은 Nociscan 플랫폼을 통해 고급 바이오마커 식별에 적합한 인구를 목표로 하여 이 모델을 미국의 다른 시장으로 확장할 계획입니다.
Aclarion, Inc. (Nasdaq: ACON) a lancé un programme visant à développer un réseau d'autres prestataires dans le New Jersey utilisant Nociscan pour les cas de blessures personnelles et d'indemnisation des travailleurs. Dirigée par le Dr. Justin Kubeck d'Ocean Pain and Spine, cette initiative vise à améliorer l'évaluation objective des patients souffrant de douleurs lombaires chroniques dans ces scénarios juridiques complexes. La technologie d'IA de Nociscan mesure les biomarqueurs dans les disques lombaires, corrélés à la douleur et à l'intégrité structurelle, fournissant des données objectives pour recommendations de traitement et défenses juridiques.
Le règlement moyen pour les recours en blessures corporelles impliquant le cou et le dos dans le New Jersey est de $918,967, tandis que les accidents liés au travail causant de telles blessures ont une indemnité moyenne nationale de $148,750. Aclarion prévoit d'étendre ce modèle à d'autres marchés américains, ciblant une population bien adaptée à l'identification avancée des biomarqueurs via la plateforme Nociscan.
Aclarion, Inc. (Nasdaq: ACON) hat ein Programm gestartet, um ein landesweites Netzwerk von Anbietern in New Jersey aufzubauen, das Nociscan für persönliche Verletzungen und Berufsgenossenschaftsfälle nutzt. Die Initiative unter der Leitung von Dr. Justin Kubeck von Ocean Pain and Spine zielt darauf ab, die objektive Bewertung von Patienten mit chronischen Rückenschmerzen in diesen komplexen rechtlichen Szenarien zu verbessern. Die KI-Technologie von Nociscan misst Biomarker in den Lendenwirbeln, die mit Schmerzen und struktureller Integrität korreliert sind, und liefert objektive Daten für Behandlungsempfehlungen und rechtliche Verteidigungen.
Der durchschnittliche Vergleichsbetrag für persönliche Verletzungsansprüche im Zusammenhang mit Nacken und Rücken in New Jersey beträgt $918,967, während arbeitsbedingte Unfälle, die solche Verletzungen verursachen, einen nationalen Durchschnittsvergleichsbetrag von $148,750 aufweisen. Aclarion plant, dieses Modell auf andere US-Märkte auszuweiten und richtet sich an eine Population, die gut für die fortschrittliche Biomarker-Identifizierung über die Nociscan-Plattform geeignet ist.
- Launch of a statewide network in New Jersey for Nociscan utilization in personal injury and workers compensation cases
- Potential for objective data from Nociscan to support higher settlements in legal cases
- Plans to expand the program to other U.S. markets
- Positioning of Nociscan as a valuable tool in the lucrative personal injury and workers compensation market
- None.
Insights
Aclarion's launch of Nociscan for personal injury and workers' compensation cases is a significant development in chronic low back pain diagnosis. The AI-driven technology's ability to identify pain biomarkers could revolutionize the evaluation process in legal settings. However, its effectiveness in reducing settlement amounts or improving patient outcomes remains unproven. The average settlements mentioned (
The introduction of Nociscan into the personal injury and workers' compensation arena could be a game-changer for legal proceedings. Objective evidence is important in these cases and Nociscan's AI-driven biomarker analysis could provide the definitive diagnosis courts often seek. However, its admissibility and weight in legal settings remain to be established. The involvement of Dr. Kubeck in educating judges and lawyers is a strategic move to gain acceptance. The potential to influence settlement amounts is significant, given the high averages cited. Yet, legal professionals should be cautious about over-reliance on a single diagnostic tool. The technology's ability to withstand cross-examination and challenges from opposing experts will be critical. Overall, while promising, Nociscan's legal impact will depend on its consistent performance and acceptance within the judicial system.
Aclarion's strategic move into the lucrative personal injury and workers' compensation market could significantly boost its revenue potential. With average settlements ranging from
Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population
Average Settlement in New Jersey for Personal Injury Claims Involving the Neck and Back is
Work-related Accidents Which Cause Neck and Back Injuries Have a National Average Settlement of
BROOMFIELD, CO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the launch of a program to develop a statewide network of providers in New Jersey to utilize Nociscan throughout the personal injury and workers compensation population.
Justin Kubeck, MD, an orthopedic surgeon and founder of Ocean Pain and Spine in Toms River, NJ will initiate a focused effort to improve the objective evaluation of chronic low back pain patients throughout the complex personal injury and workers compensation system that aims to provide the right treatments and financial compensation to patients suffering from injury.
“The personal injury and workers compensation ecosystem involves a discrete number of judges and lawyers who work to adjudicate claims leveraging the expertise of physicians dedicated to understanding this unique segment of the healthcare system. The nature of these claims mandates an objective and definitive diagnosis, knowing that the diagnosis may well be challenged in a legal setting. The use of Nociscan can be a powerful objective measurement tool to provide a strong case for supporting an appropriate treatment pathway,” said Dr. Kubeck. “Over the next several months, I will be working to educate the network of judges and lawyers who determine the appropriateness of recommended treatments on the value Nociscan brings to my patients and the value I think it can bring to improving the workers compensation and personal injury evaluation process.”
Workers compensation and personal injury claims involving the neck and back have significant financial implications for workers, employers, and insurance companies. Although there are many factors that go into the final settlement or jury verdict associated with these cases, whether surgical intervention is required or not is often a clear delineating point for the size of the settlement. Because Nociscan directly measures biomarkers in the lumbar disc correlated to pain and structural integrity, Nociscan is positioned to provide important objective data that providers can use as they formulate and defend their recommended treatment plan.
Ryan Bond, Chief Strategy Officer of Aclarion, commented, “Once established in New Jersey, we will target other markets throughout the United States to replicate the success of the NJ market. We believe this population is the perfect fit for the use of advanced biomarker identifications correlated to pain and available exclusively through the Nociscan platform.”
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
646.823.8656
ksmith@pcgadvisory.com
Media Contacts:
Jodi Lamberti
SPRIG Consulting
612.812.7477
jodi@sprigconsulting.com
FAQ
What is Aclarion's new initiative for Nociscan in New Jersey?
Who is leading Aclarion's Nociscan initiative in New Jersey?
What is the average settlement for personal injury claims involving neck and back in New Jersey?
How does Nociscan technology benefit personal injury and workers compensation cases?
